Allogene Therapeutics, Inc.

Healthcare

NASDAQ:ALLO · NASDAQ Global Select

Market Cap $477.98M Beta 0.46 P/E (TTM) -2.7

$2.00 +1.02%

+$0.02 today

52W Low $0.98High $4.46

Vol 14.38M · Avg 10.19M

EPS (TTM) -$0.72Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+63.93%

Period High

$3.06

Period Low

$1.03

Latest

$2.00

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Achieve Life Sciences, Inc.

NASDAQ:ACHV

$507.65M

Cabaletta Bio, Inc.

NASDAQ:CABA

$467.71M

Kyverna Therapeutics, Inc.

NASDAQ:KYTX

$348.58M

Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

$346.98M

Atea Pharmaceuticals, Inc.

NASDAQ:AVIR

$344.52M

Editas Medicine, Inc.

NASDAQ:EDIT

$252.30M

Voyager Therapeutics, Inc.

NASDAQ:VYGR

$223.26M

Caribou Biosciences, Inc.

NASDAQ:CRBU

$157.24M

Humacyte, Inc.

NASDAQ:HUMA

$155.15M

Immutep Limited

NASDAQ:IMMP

$55.41M

What is the latest ALLO filing?

The latest filing shown is DEFA14A dated May 28, 2026.

How many recent filings does ALLO have?

Intrinsic Alpha currently shows 20 recent filings for ALLO.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.